<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">EBM</journal-id>
<journal-id journal-id-type="hwp">spebm</journal-id>
<journal-title>Experimental Biology and Medicine</journal-title>
<issn pub-type="ppub">1535-3702</issn>
<issn pub-type="epub">1535-3699</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1535370213488484</article-id>
<article-id pub-id-type="publisher-id">10.1177_1535370213488484</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Minireviews</subject>
<subj-group subj-group-type="heading">
<subject>Neuroscience</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Oxidation and ubiquitination in neurodegeneration</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Riederer</surname><given-names>Beat M</given-names></name>
<xref ref-type="aff" rid="aff1-1535370213488484">1</xref>
<xref ref-type="aff" rid="aff2-1535370213488484">2</xref>
<xref ref-type="corresp" rid="corresp1-1535370213488484"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Leuba</surname><given-names>Geneviève</given-names></name>
<xref ref-type="aff" rid="aff1-1535370213488484">1</xref>
<xref ref-type="aff" rid="aff3-1535370213488484">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>ElHajj</surname><given-names>Zeinab</given-names></name>
<xref ref-type="aff" rid="aff1-1535370213488484">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1535370213488484"><label>1</label>Proteomic Unit, Centre for Psychiatric Neuroscience, Department of Psychiatry, CHUV, CERY, Prilly-Lausanne, CH-1008, Switzerland</aff>
<aff id="aff2-1535370213488484"><label>2</label>Department of Fundamental Neurosciences, University of Lausanne, Faculty of Biology and Medicine, CH-1011, Lausanne, Switzerland</aff>
<aff id="aff3-1535370213488484"><label>3</label>Service of Old Age Psychiatry, Centre for Psychiatric Neuroscience, Department of Psychiatry, CHUV, CERY, Prilly-Lausanne, CH-1008, Switzerland</aff>
<author-notes>
<corresp id="corresp1-1535370213488484">Beat M Riederer. Email: <email>beat.riederer@unil.ch</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2013</year>
</pub-date>
<volume>238</volume>
<issue>5</issue>
<issue-title>Mini-Review Annual Issue</issue-title>
<fpage>519</fpage>
<lpage>524</lpage>
<permissions>
<copyright-statement>© The Author(s) 2013 by the Society for Experimental Biology and Medicine</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="society">The Society for Experimental Biology and Medicine</copyright-holder>
</permissions>
<abstract>
<p>It is widely accepted that protein oxidation is involved in a variety of diseases, including neurodegenerative diseases. Especially during aging, a reduction in anti-oxidant defence mechanisms leads to an increased formation of free radical oxygen species and consequently results in a damage of proteins, including mitochondrial and synaptic ones. Even those proteins involved in repair and protein clearance via the ubiquitin proteasome and lysosomal system are subject to damage and show a reduced function. Here, we will discuss a variety of mechanisms and provide examples where cognition is affected and where repair mechanisms are no longer sufficient to compensate for a dysfunction of damaged proteins or even may become toxic. Next to physiological deficits, an accumulation of deficient proteins in aggresomes may occur and result in a formation of pathological hallmark structures typical for aging and disease. A major challenge is how to prevent aberrant oxidation, given that oxidation plays an essential role in aging and neurodegenerative diseases. Particularly interesting are the possibilities to reduce the formation of radical oxygen species leading to a dysfunction of protein repair and protein clearance, or to a formation of toxic byproducts accelerating neurodegeneration.</p>
</abstract>
<kwd-group>
<kwd>Alzheimer's disease</kwd>
<kwd>oxidation</kwd>
<kwd>mitochondria</kwd>
<kwd>neurodegeneration</kwd>
<kwd>tau protein</kwd>
<kwd>ubiquitination</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-1535370213488484" sec-type="intro"><title>Introduction</title>
<p>Oxygen plays an important role for most living organisms, with benefic and also adverse effects. Reactive oxygen species (ROS), i.e. unpaired electrons or free radicals, are produced by a variety of mechanisms<sup><xref ref-type="bibr" rid="bibr1-1535370213488484">1</xref>,<xref ref-type="bibr" rid="bibr2-1535370213488484">2</xref></sup> and often are byproducts of metabolic processes that lead to oxidation, peroxidation, glycation or nitrosylation. Most biological systems have developed different strategies how to neutralize free radicals, i.e. by different enzymes such as glutathione, thioredoxins, peroxiredoxins, reductases, phosphatases and kinases involved in redox regulation or transcription factors of the <italic>Jun</italic> and <italic>Fos</italic> families or NF-kB.<sup><xref ref-type="bibr" rid="bibr3-1535370213488484">3</xref></sup> The cell has also repair mechanisms in place, which involve chaperones and heatshock proteins to reverse conformational changes and, if not possible, to activate enzymatic clearance mechanisms via the ubiquitin proteasome system (UPS) or via lysosome-autophagy. This may eventually create problems when proteins cannot be repaired or degraded and then become toxic for the metabolism.<sup><xref ref-type="bibr" rid="bibr4-1535370213488484">4</xref></sup> There are a variety of strategies how to affect the dangerous development and attack noxious effects.</p>
<p>With aging, the formation of ROS is increasing, becoming more important for age-related diseases, and may result in oxidative damage, favouring the progression of many pathologies.<sup><xref ref-type="bibr" rid="bibr5-1535370213488484">5</xref></sup> Therefore, it seems essential to look for strategies that tackle the problem early on during oxidative stress. In this minireview, we will look at critical and common points between different diseases regarding oxidation and the role of ubiquitination. Although some of the deficient mechanisms are not directly at the origin of the disease, they may affect the progression of the pathology and provide potential therapeutic targets.</p>
<sec id="sec2-1535370213488484"><title>Role of oxidation in aging, mitochondrial and synaptic defects</title>
<p>Normal brain aging is characterized by cognitive decline, with a moderate neuron loss and synaptic changes.<sup><xref ref-type="bibr" rid="bibr6-1535370213488484">6</xref><xref ref-type="bibr" rid="bibr7-1535370213488484"/>–<xref ref-type="bibr" rid="bibr8-1535370213488484">8</xref></sup> Increasing evidence suggests that synaptic mitochondrial dysfunction is strongly associated with synaptic failure in many neurodegenerative diseases and represents an early event in neurodegenerative diseases such as Alzheimer's disease (AD).<sup><xref ref-type="bibr" rid="bibr9-1535370213488484">9</xref>,<xref ref-type="bibr" rid="bibr10-1535370213488484">10</xref></sup> Synaptic mitochondria undergo multiple malfunctions including Aß accumulation, increased oxidative stress, decreased respiration and compromised calcium handling.<sup><xref ref-type="bibr" rid="bibr11-1535370213488484">11</xref></sup> The microtubule-associated tau protein probably plays a crucial role, since tau oligomers may impair memory and induce synaptic and mitochondrial dysfunction and neurodegeneration in mouse models.<sup><xref ref-type="bibr" rid="bibr12-1535370213488484">12</xref>,<xref ref-type="bibr" rid="bibr13-1535370213488484">13</xref></sup> Tau seems instrumental and depends on a variety of modification such as phosphorylation, acetylation, glycosylation and ubiquitination and, together with Aß peptides, to have noxious effects on neurons.<sup><xref ref-type="bibr" rid="bibr14-1535370213488484">14</xref>,<xref ref-type="bibr" rid="bibr15-1535370213488484">15</xref></sup> Oxidation may affect specific receptors and disturb the N-methyl-D-aspartate (NMDA) receptor excitation and inhibition balance.<sup><xref ref-type="bibr" rid="bibr16-1535370213488484">16</xref></sup> Such receptors comprise cysteine switches and are a molecular model for the action of S-nitrosylation,<sup><xref ref-type="bibr" rid="bibr17-1535370213488484">17</xref></sup> therefore sensitive to oxidation. Redox modulation by S-nitrosylation may also contribute to protein misfolding, changes in mitochondria dynamics and neuronal damage in neurodegenerative disorders such as Alzheimer's and Parkinson's disease, and may be at the origin of foldopathies.<sup><xref ref-type="bibr" rid="bibr18-1535370213488484">18</xref></sup> Oxidative stress and consequences of oxidation are at the origin of many aging-related and pathogenic mechanisms which have been extensively discussed.<sup><xref ref-type="bibr" rid="bibr19-1535370213488484">19</xref></sup> A variety of cells are involved in these events such as glia, microglia and neurons, and mechanisms include mitochondrial impairment in synapses, the generation of free radical oxygen species and an increase in cell toxicity. This may have an effect on energy transfer mechanisms and stimulate microgliosis and neuroinflammatory events via cytokines. Cytoskeletal abnormalities may result in an alteration of axonal and dendritic transport and in an accumulation of aggregates. A general increase in oxidative stress leads to mitochondrial failure, to an activation of excitotoxicity and caspase cascades, to DNA damage and to an increased vulnerability of neurons for neurodegeneration.<sup><xref ref-type="bibr" rid="bibr19-1535370213488484">19</xref></sup> Increased oxidation affects protein conformation, therefore leading to dysfunction. Misfolding of proteins, summarized as <italic>foldopathies</italic>, is also known as proteinopathies or conformational diseases. They comprise clinically and pathologically diverse disorders in which specific proteins accumulate in cells and tissues, and are found as aggregates or inclusion bodies.<sup><xref ref-type="bibr" rid="bibr20-1535370213488484">20</xref>,<xref ref-type="bibr" rid="bibr21-1535370213488484">21</xref></sup> They include over 40 diseases, including Alzheimer's, Parkinson's and Huntington disease, amyotrophic lateral sclerosis (ALS), prion disease, inclusion body myopathy and systemic amyloidoses. Advanced age is an important risk factor for most proteinopathies, in parts because the ability to degrade or remove abnormal proteins by ubiquitination and the proteasome are compromised. In several neurodegenerative diseases, tau and α-synuclein proteins play a role and may by summarised as <italic>tauopathies</italic> or <italic>synucleinopathies</italic>. A variety of proteomic studies have clearly identified that during aging mitochondrial dysfunction and free radical accumulation may lead to increased oxidation and dysfunction in protein degradation.<sup><xref ref-type="bibr" rid="bibr20-1535370213488484">20</xref><xref ref-type="bibr" rid="bibr21-1535370213488484"/><xref ref-type="bibr" rid="bibr22-1535370213488484"/><xref ref-type="bibr" rid="bibr23-1535370213488484"/>–<xref ref-type="bibr" rid="bibr24-1535370213488484">24</xref></sup></p>
<p>Lipofuscin, also called dark fat, aging pigment or ceroid, is of yellow–brown appearance. It is a ‘pathologically derived storage material’ composed by two-thirds of proteins and one-thirds of lipids, containing also iron and copper. It is detectable across a broad spectrum by fluorescence microscopy (540–650 nm). Free radicals influence senescence of mitochondria and reduce lysosome function. Furthermore, a dysfunction of the proteasome may contribute to an accumulation due to an incomplete elimination of cellular ‘garbage’. Accumulation of ceroids represents a consequence of failed degradation of mitochondria or can be due to mutations in enzymes of the lysosomal system.<sup><xref ref-type="bibr" rid="bibr25-1535370213488484">25</xref></sup></p>
<p>Since oxidative stress influences early pathogenic mechanisms involved in neurodegeneration, it is among the main targets in therapeutic strategies to increase oxidative defence mechanisms. So far, anti-oxidant treatments in clinical trials showed modest positive effects in cognitive function, possibly related to the fact that either anti-oxidants might not cross the blood–brain barrier, or that late-stage AD patients were used.<sup><xref ref-type="bibr" rid="bibr11-1535370213488484">11</xref>,<xref ref-type="bibr" rid="bibr26-1535370213488484">26</xref></sup> There are a variety of therapeutic options.<sup><xref ref-type="bibr" rid="bibr27-1535370213488484">27</xref>,<xref ref-type="bibr" rid="bibr28-1535370213488484">28</xref></sup> To be effective to prevent ROS formation, one needs to start early with a treatment. It is well known that certain products and food components have a positive effect on mental health and slow down cognitive decline with aging<sup><xref ref-type="bibr" rid="bibr29-1535370213488484">29</xref></sup> by affecting oxidative stress, inflammation, atherosclerosis, cancer formation and much more, as reviewed recently.<sup><xref ref-type="bibr" rid="bibr3-1535370213488484">3</xref>,<xref ref-type="bibr" rid="bibr30-1535370213488484">30</xref></sup> Therefore, diet may be a non-negligible factor to affect the progression of neurodegenerative disorders. However, in Huntington's disease, a neurodegenerative disorder that is characterized by polyglutamine aggregation, the anti-oxidant curcumin had rather an opposite effect and induced expansion of polyglutamine chains, aggregation of huntingtin, with a proteasomal dysfunction and eventually led to cell death.<sup><xref ref-type="bibr" rid="bibr31-1535370213488484">31</xref></sup> This suggests that a variety of mechanisms involved may react in different ways to anti-oxidant substances.</p>
</sec>
<sec id="sec3-1535370213488484"><title>Dysregulation of protein repair and proteasome</title>
<p>The UPS is instrumental for protein repair and turnover and consists of a complex multistep enzymatic pathway, being a special challenge for the postmitotic neurons to maintain synaptic plasticity and self-renewal.<sup><xref ref-type="bibr" rid="bibr4-1535370213488484">4</xref>,<xref ref-type="bibr" rid="bibr32-1535370213488484">32</xref>,<xref ref-type="bibr" rid="bibr33-1535370213488484">33</xref></sup> Ubiquitin is a small molecule used to target damaged proteins for repair or proteins destined for degradation. The UPS is responsible for breakdown of 90% of abnormal proteins or short-lived proteins (t1/2 hours to days).<sup><xref ref-type="bibr" rid="bibr34-1535370213488484">34</xref></sup></p>
<p>Oxidised and misfolded proteins may be repaired by several heatshock proteins (hsp27, hsp70, carboxyl terminus of the hsc-70-interacting protein, also called CHIP),<sup><xref ref-type="bibr" rid="bibr35-1535370213488484">35</xref>,<xref ref-type="bibr" rid="bibr36-1535370213488484">36</xref></sup> and a repair is essential since several proteins may exert at least at some stage an ‘ad hoc’ toxic effect.<sup><xref ref-type="bibr" rid="bibr37-1535370213488484">37</xref></sup> In a variety of diseases, a genetic variation leads to the expression of mutant proteins, such proteins being able to overload the UPS and consequently accumulate in form of protein aggregates or aggresomes as a result of ligase deficiency in the process of proteasome function.<sup><xref ref-type="bibr" rid="bibr33-1535370213488484">33</xref></sup> In ALS, a fatal motor neuron disease, neurofilament proteins accumulate in the soma of motoneurons and superoxide dismutase 1 (SOD1)-mediated toxicity seems at the origin.<sup><xref ref-type="bibr" rid="bibr38-1535370213488484">38</xref></sup> In Huntington disease, a huntingtin mutation results in polyglutamine accumulation. In Parkinson's disease, there is a mutated parkin (an E3 ubiquitin ligase) and α-synuclein as substrate that accumulate in Lewy bodies. A recent review illustrates the role of oxidation of dopamine to aminochrome (a precursor of the neuromelanin) that induces (i) the formation of α-synuclein protofibrils that inactivate chaperone-mediated autophagy; (ii) the formation of adducts with α- and β-tubulin, which induce the aggregation of the microtubules required for the fusion of autophagy vacuoles and lysosomes.<sup><xref ref-type="bibr" rid="bibr39-1535370213488484">39</xref></sup> In AD, toxic forms of tau and Aß affect the UPS system<sup><xref ref-type="bibr" rid="bibr40-1535370213488484">40</xref></sup> and favour the formation of senile plaques and by paired helical filaments (PHFs) instead of degradation and clearance. In Down syndrome, Aß accumulates with age in the frontal cortex and oxidative damage may contribute to the onset and progression of AD pathogenesis.<sup><xref ref-type="bibr" rid="bibr41-1535370213488484">41</xref></sup> In AD frontal cortex, several anti-oxidants such as glutathione, glutathione peroxidase, glutathione-S-transferase and superoxide dismutase are reduced and this suggests an oxidative stress-dependant reduction of oxidation defence mechanisms, contributing to mitochondrial dysfunction and loss of synapses.<sup><xref ref-type="bibr" rid="bibr42-1535370213488484">42</xref></sup></p>
<p>Oxidation affects also directly the UPS, since several proteins of the proteasome are oxidized and also ubiquitinated, influencing protein repair and clearance. In addition, several proteins may have a toxic effect in vulnerable cells and induce cell death. One of these proteins is the Ubiquitin C-terminal hydrolase L1 (Uch-L1), which plays a central role in the UPS, and is essential for de-ubiquitination.<sup><xref ref-type="bibr" rid="bibr43-1535370213488484">43</xref></sup> It was also shown to be required for normal synaptic and cognitive function, since it can restore Aß-induced decrease of synaptic function and contextual memory in an AD mouse model.<sup><xref ref-type="bibr" rid="bibr44-1535370213488484">44</xref></sup> It was found oxidized in AD brain and its soluble levels were inversely proportional to the number of neurofibrillary tangles (NFTs).<sup><xref ref-type="bibr" rid="bibr30-1535370213488484">30</xref>,<xref ref-type="bibr" rid="bibr45-1535370213488484">45</xref></sup> These reports all point to an important role of the UPS in neurodegenerative diseases and suggest that protein alteration due to oxidation or to the lack of protein repair may strongly contribute to degenerative events.</p>
</sec>
<sec id="sec4-1535370213488484"><title>Relationship between oxidation and ubiquitination</title>
<p>If we have to come up with a viable model for the generation of sporadic AD, it seems that age-related increase in oxidation and reduction of anti-oxidant defence mechanisms may play a major role in the generation of ROS via mitochondrial dysfuntion in synapses, combined with a dysregulation of repair mechanisms. This may also depend on the individual defence mechanisms of cells and point to a selective cellular vulnerability for dysfunction of redox and ubiquitination mechanisms.</p>
<p>In <xref ref-type="fig" rid="fig1-1535370213488484">Figure 1</xref>, we have summarized a variety of mechanisms that play an essential part in the formation of toxic products and in the lack of correct clearance of noxious byproducts eventually leading to cell death. Several proteins may play a key role and unless correctly cleared affect the cell metabolism. This is exemplified for tau proteins and for a particular Aß peptide form, a derivative from amyloid precursor protein (APP). At first, oxidative damage resulting from oxidative stress at synaptic or cellular level may increase free radicals and protein oxidation. Such proteins may be repaired or eventually tagged for degradation by ubiquitination. During aging, this mechanism is disturbed<sup><xref ref-type="bibr" rid="bibr46-1535370213488484">46</xref>,<xref ref-type="bibr" rid="bibr47-1535370213488484">47</xref></sup> and, instead of protein clearance, may result in the accumulation of ubiquitinated proteins in form of aggresomes.<sup><xref ref-type="bibr" rid="bibr48-1535370213488484">48</xref></sup> Some proteins may even affect the correct function of the proteasome.<sup><xref ref-type="bibr" rid="bibr49-1535370213488484">49</xref></sup> Depending on circumstances, vulnerable cells may respond to some of the modified proteins such as phospho-forms of tau proteins and/or microfibrils of tau as well as to specific cleavage forms of APP and consequently to Aß forms and their toxic effects.<sup><xref ref-type="bibr" rid="bibr16-1535370213488484">16</xref>,<xref ref-type="bibr" rid="bibr50-1535370213488484">50</xref></sup> However, recent results suggest that there is no direct correlation between the level of pathological tau and the extent of aggresome formation in different brain areas.<sup><xref ref-type="bibr" rid="bibr51-1535370213488484">51</xref></sup> Therefore, some neurons may be more vulnerable than others to the toxicity of some proteins in different parts of the brain.<sup><xref ref-type="bibr" rid="bibr52-1535370213488484">52</xref></sup> For example, we can mention the sporadic formation of a toxic triad of tau, Aß and fyn in hippocampus and neocortex in AD,<sup><xref ref-type="bibr" rid="bibr50-1535370213488484">50</xref></sup> the presence of abnormal phosphorylated neurofilaments in motoneurons in ALS,<sup><xref ref-type="bibr" rid="bibr38-1535370213488484">38</xref></sup> the accumulation of huntingtin in the striatum in Huntington's disease<sup><xref ref-type="bibr" rid="bibr53-1535370213488484">53</xref></sup> or the formation of toxic aminochromes in the substantita nigra in Parkinson's disease.<sup><xref ref-type="bibr" rid="bibr39-1535370213488484">39</xref></sup>
<fig id="fig1-1535370213488484" position="float"><label>Figure 1</label><caption><p>The normal pathway of protein repair, ubiquitination and protein clearance by the proteasome system is outlined with grey arrows. Different factors such as oxidative stress, mitochondrial deficits or mutations may lead to an increased oxidation of proteins. They may also affect mechanisms involved in protein repair and block protein clearance. As a consequence, proteins are becoming increasingly ubiquitinated and form aggresomes during normal aging. In addition, some of these proteins may even have a toxic effect in vulnerable neurons and lead to the formation of hallmark structures in neurodegenerative pathologies, and finally to cell death</p></caption><graphic xlink:href="10.1177_1535370213488484-fig1.tif"/>
</fig></p>
</sec>
<sec id="sec5-1535370213488484"><title>What are target mechanisms of potential interest?</title>
<p>A main objective in the search for therapeutic treatments is how to reduce protein toxicity and increase protein degradation and clearance.<sup><xref ref-type="bibr" rid="bibr34-1535370213488484">34</xref>,<xref ref-type="bibr" rid="bibr54-1535370213488484">54</xref></sup> Recent attempts focus on the understanding of tau aggregation and how to interrupt the formation of toxic tau filaments.<sup><xref ref-type="bibr" rid="bibr55-1535370213488484">55</xref></sup> Late onset AD provides a challenge to identify markers for different neurodegenerative diseases. There is a need for a clinical evaluation of several oxidation components in the blood such as protein carbonyls, nitrite and glutathione, catalase, α-tocopherol, calcium, Se and Zn as possible predictive markers of neurodegenerative diseases.<sup><xref ref-type="bibr" rid="bibr56-1535370213488484">56</xref>,<xref ref-type="bibr" rid="bibr57-1535370213488484">57</xref></sup> Indeed, elevated labile Cu levels in cortical brain tissue were associated with oxidative stress in AD, as well as a deranged Cu homeostasis.<sup><xref ref-type="bibr" rid="bibr58-1535370213488484">58</xref></sup> A causal role of mitochondrial bioenergetics deficits and brain hypometabolism coupled with increased mitochondrial oxidative stress is probable in AD, as well as a shift from glucose-driven to the lesser efficient ketogenic pathway.<sup><xref ref-type="bibr" rid="bibr59-1535370213488484">59</xref></sup> Efficient strategies are based on compensation for oxidative stress related to synaptic mitochondria and favouring glucose-driven metabolic activities. A mitochondrion-specific anti-oxidant treatment for AD remains very hypothetical. However, using endogenous anti-oxidant defence mechanisms and an appropriate nutrition plan of anti-oxidant ingredients such as citrulline, taurine, creatine, polyphenols, selenium, zinc, vitamin A, C and E may help to reduce progression of mental decline.<sup><xref ref-type="bibr" rid="bibr27-1535370213488484">27</xref>,<xref ref-type="bibr" rid="bibr29-1535370213488484">29</xref>,<xref ref-type="bibr" rid="bibr52-1535370213488484">52</xref></sup> Targeting factors that damage mitochondria with acetyl-<sc>l</sc>-carnitine or R-alpha-lipoic acid helps reversing effects of mitochondrial damage and eliminating the imbalance in energy production and Aß oxidation, thus making anti-oxidants a promising alternative for an early AD prevention ?<sup><xref ref-type="bibr" rid="bibr28-1535370213488484">28</xref></sup> Xanthene food dye, such as erythrosine B, was reported as novel modulator of Aß aggregation and reduced Aß-associated impaired cell function and becomes an attractive molecule since it is already Food and Drug Administration (FDA)-approved.<sup><xref ref-type="bibr" rid="bibr60-1535370213488484">60</xref></sup> <italic>N</italic>-acetyl-cysteine is another promising molecule to improve action of glutathione as therapeutic strategy to reduce oxidative stress<sup><xref ref-type="bibr" rid="bibr61-1535370213488484">61</xref></sup>, because it can reverse memory impairment in aged SAMP8 mice<sup><xref ref-type="bibr" rid="bibr62-1535370213488484">62</xref></sup> or reduce oxidative stress in Schizophrenia.<sup><xref ref-type="bibr" rid="bibr63-1535370213488484">63</xref></sup> However, to test the efficacy of any treatment or specific diets, it is essential to have specific tools to measure and quantify oxidation, S-nitrosylation or carbonylation levels in blood and cerebrospinal fluid and to determine target proteins involved in oxidative stress.<sup><xref ref-type="bibr" rid="bibr30-1535370213488484">30</xref>,<xref ref-type="bibr" rid="bibr64-1535370213488484">64</xref></sup></p>
</sec>
</sec>
<sec id="sec6-1535370213488484" sec-type="conclusions"><title>Conclusion</title>
<p>In neurodenegenerative diseases, a variety of cellular mechanisms are involved and are in relation to ongoing basic cellular events. The initial question, whether oxidation and ubitquitination is essential, can be answered with a clear <bold>Yes</bold>. Oxidative stress affects many processes in mitochondria and synapses with consequences for repair mechanisms and aggresome formation as well as pathological structures in a variety of neurodegenerative diseases. However, oxidation and UPS dysregulation is probably not the main cause for most neurodegenerative diseases, for the exception of ALS where SOD1 mutations are detrimental. Protein oxidation and conformational changes may contribute to changes in protein function and so influence the progression of neurodegeneration. One point that transpires is that oxidation of proteins is a non-negligible factor during aging and may provide many targets to develop therapeutic strategies how to improve the redox balance. Furthermore, repair mechanisms are essential to get the specific pathways on the right track and correct errors, to grant a proper metabolic control and to favour correct protein repair.</p>
</sec>
</body>
<back>
<sec id="sec7-1535370213488484"><title>Author contributions</title>
<p>BMR has written the minireview, GL has contributed with scientific comments and constructive critique and ZE has done the literature search and contributed with scientific data.</p>
</sec>
<ack><title>Acknowledgement</title>
<p>Zeinab ElHajj is supported by the CNRS of Lebanon.</p></ack>
<ref-list><title>References</title>
<ref id="bibr1-1535370213488484"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stadtman</surname><given-names>ER</given-names></name></person-group>. <article-title>Protein oxidation and aging</article-title>. <source>Free Rad Res</source> <year>2006</year>; <volume>40</volume>: <fpage>1250</fpage>–<lpage>8</lpage>.</citation></ref>
<ref id="bibr2-1535370213488484"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Riederer</surname><given-names>BM</given-names></name><name><surname>Leuba</surname><given-names>G</given-names></name><name><surname>Vernay</surname><given-names>A</given-names></name><name><surname>Riederer</surname><given-names>IM</given-names></name></person-group>. <article-title>The role of the ubiquitin proteasome system in Alzheimer's disease</article-title>. <source>Exp Biol Med</source> <year>2011</year>; <volume>236</volume>: <fpage>268</fpage>–<lpage>76</lpage>.</citation></ref>
<ref id="bibr3-1535370213488484"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>SC</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Kannappan</surname><given-names>R</given-names></name><name><surname>Reuter</surname><given-names>S</given-names></name><name><surname>Dougherty</surname><given-names>PM</given-names></name><name><surname>Aggarwal</surname><given-names>BB</given-names></name></person-group>. <article-title>Role of nuclear factor kappaB-mediated inflammatory pathways in cancer-related symptoms and their regulation by nutritional agents</article-title>. <source>Exp Biol Med</source> <year>2011</year>; <volume>236</volume>: <fpage>658</fpage>–<lpage>71</lpage>.</citation></ref>
<ref id="bibr4-1535370213488484"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ihara</surname><given-names>Y</given-names></name><name><surname>Morishima-Kawashima</surname><given-names>M</given-names></name><name><surname>Nixon</surname><given-names>R</given-names></name></person-group>. <article-title>The ubiquitin-proteasome system and the autophagic-lysosomal system in Alzheimer disease</article-title>. <source>CSH Persp Med</source> <year>2012</year>; <volume>2</volume>: <fpage>a006361</fpage>–<lpage>a006361</lpage>.</citation></ref>
<ref id="bibr5-1535370213488484"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>MP</given-names></name></person-group>. <article-title>How mitochondria produce reactive oxygen species</article-title>. <source>Biochem J</source> <year>2009</year>; <volume>417</volume>: <fpage>1</fpage>–<lpage>13</lpage>.</citation></ref>
<ref id="bibr6-1535370213488484"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Mallory</surname><given-names>M</given-names></name><name><surname>Hansen</surname><given-names>L</given-names></name><name><surname>DeTeresa</surname><given-names>R</given-names></name><name><surname>Terry</surname><given-names>RD</given-names></name></person-group>. <article-title>Quantitative synaptic alterations in the human neocortex during normal aging</article-title>. <source>Neurology</source> <year>1993</year>; <volume>43</volume>: <fpage>192</fpage>–<lpage>7</lpage>.</citation></ref>
<ref id="bibr7-1535370213488484"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anderton</surname><given-names>BH</given-names></name></person-group>. <article-title>Ageing of the brain</article-title>. <source>Mech Ageing Devel</source> <year>2002</year>; <volume>123</volume>: <fpage>811</fpage>–<lpage>17</lpage>.</citation></ref>
<ref id="bibr8-1535370213488484"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reddy</surname><given-names>PH</given-names></name><name><surname>Mani</surname><given-names>G</given-names></name><name><surname>Park</surname><given-names>BS</given-names></name><etal/></person-group>. <article-title>Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction</article-title>. <source>J Alz Dis</source> <year>2005</year>; <volume>7</volume>: <fpage>103</fpage>–<lpage>17</lpage>.</citation></ref>
<ref id="bibr9-1535370213488484"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baloyannis</surname><given-names>SJ</given-names></name></person-group>. <article-title>Mitochondria are related to synaptic pathology in Alzheimer's disease</article-title>. <source>Int J Alz Dis</source> <year>2011</year>; <volume>2011</volume>: <fpage>1</fpage>–<lpage>7</lpage>.</citation></ref>
<ref id="bibr10-1535370213488484"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Yan</surname><given-names>SS</given-names></name></person-group>. <article-title>Synaptic mitochondrial pathology in Alzheimer's disease</article-title>. <source>Antioxid Redox Signal</source> <year>2012</year>; <volume>16</volume>: <fpage>1467</fpage>–<lpage>75</lpage>.</citation></ref>
<ref id="bibr11-1535370213488484"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reddy</surname><given-names>PH</given-names></name><name><surname>Tripathi</surname><given-names>R</given-names></name><name><surname>Troung</surname><given-names>Q</given-names></name><name><surname>Tirumala</surname><given-names>K</given-names></name><name><surname>Reddy</surname><given-names>TP</given-names></name><name><surname>Anekonda</surname><given-names>V</given-names></name><name><surname>Shirendeb</surname><given-names>UP</given-names></name><name><surname>Calkins</surname><given-names>MJ</given-names></name><name><surname>Reddy</surname><given-names>AP</given-names></name><name><surname>Mao</surname><given-names>P</given-names></name><name><surname>Manczak</surname><given-names>M</given-names></name></person-group>. <article-title>Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: implications to mitochondria-targeted antioxidant therapeutics</article-title>. <source>Biochim Biophys Acta</source> <year>2012</year>; <volume>1822</volume>: <fpage>639</fpage>–<lpage>49</lpage>.</citation></ref>
<ref id="bibr12-1535370213488484"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lasagna-Reeves</surname><given-names>CA</given-names></name><name><surname>Castillo-Carranza</surname><given-names>DL</given-names></name><name><surname>Sengupta</surname><given-names>U</given-names></name><name><surname>Clos</surname><given-names>AL</given-names></name><name><surname>Jackson</surname><given-names>GR</given-names></name><name><surname>Kayed</surname><given-names>R</given-names></name></person-group>. <article-title>Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice</article-title>. <source>Mol Neurodeg</source> <year>2011</year>; <volume>6</volume>: <fpage>1</fpage>–<lpage>14</lpage>.</citation></ref>
<ref id="bibr13-1535370213488484"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoover</surname><given-names>BR</given-names></name><name><surname>Reed</surname><given-names>MN</given-names></name><name><surname>Su</surname><given-names>J</given-names></name><name><surname>Penrod</surname><given-names>RD</given-names></name><name><surname>Kotilinek</surname><given-names>LA</given-names></name><name><surname>Grant</surname><given-names>MK</given-names></name><name><surname>Pitstick</surname><given-names>RP</given-names></name><name><surname>Carlson</surname><given-names>GA</given-names></name><name><surname>Lanier</surname><given-names>LM</given-names></name><name><surname>Yuan</surname><given-names>L-L</given-names></name><name><surname>Ashe</surname><given-names>KH</given-names></name><name><surname>Liao</surname><given-names>D</given-names></name></person-group>. <article-title>Tau mislocalzation to dendritic spines mediates synaptic dysfunction independently of neurodegeneration</article-title>. <source>Neuron</source> <year>2010</year>; <volume>68</volume>: <fpage>1067</fpage>–<lpage>81</lpage>.</citation></ref>
<ref id="bibr14-1535370213488484"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Min</surname><given-names>S-W</given-names></name><name><surname>Cho</surname><given-names>S-H</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Schroeder</surname><given-names>S</given-names></name><name><surname>Haroutiunian</surname><given-names>V</given-names></name><name><surname>Seeley</surname><given-names>WW</given-names></name><name><surname>Huang</surname><given-names>EJ</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Mukherjee</surname><given-names>C</given-names></name><name><surname>Meyers</surname><given-names>D</given-names></name><name><surname>Cole</surname><given-names>PA</given-names></name><name><surname>Ott</surname><given-names>M</given-names></name><name><surname>Gan</surname><given-names>L</given-names></name></person-group>. <article-title>Acetylation of tau inhibits its degradation and contributes to tauopathy</article-title>. <source>Neuron</source> <year>2010</year>; <volume>67</volume>: <fpage>953</fpage>–<lpage>66</lpage>.</citation></ref>
<ref id="bibr15-1535370213488484"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mandelkow</surname><given-names>E-M</given-names></name><name><surname>Mandelkow</surname><given-names>E</given-names></name></person-group>. <article-title>Biochemistry and cell biology of tau protein in neurofibrillary degeneration</article-title>. <source>CSH Perspect Med</source> <year>2012</year>; <volume>2</volume>: <fpage>a006247</fpage>–<lpage>a006247</lpage>.</citation></ref>
<ref id="bibr16-1535370213488484"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roberson</surname><given-names>ED</given-names></name><name><surname>Halabisky</surname><given-names>B</given-names></name><name><surname>Yoo</surname><given-names>JW</given-names></name><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Chin</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>F</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Hamto</surname><given-names>P</given-names></name><name><surname>Devidze</surname><given-names>N</given-names></name><name><surname>Yu</surname><given-names>G-Q</given-names></name><name><surname>Palop</surname><given-names>JJ</given-names></name><name><surname>Noebels</surname><given-names>JL</given-names></name><name><surname>Mucke</surname><given-names>L</given-names></name></person-group>. <article-title>Amyloid-ß/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease</article-title>. <source>J Neurosci</source> <year>2011</year>; <volume>31</volume>: <fpage>700</fpage>–<lpage>11</lpage>.</citation></ref>
<ref id="bibr17-1535370213488484"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lipton</surname><given-names>SA</given-names></name><name><surname>Choi</surname><given-names>Y-B</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Godzik</surname><given-names>A</given-names></name><name><surname>Bankston</surname><given-names>LA</given-names></name></person-group>. <article-title>Cysteine regulation of protein function – as exemplified by NMDA-receptor modulation</article-title>. <source>Trends Neurosci</source> <year>2002</year>; <volume>25</volume>: <fpage>474</fpage>–<lpage>80</lpage>.</citation></ref>
<ref id="bibr18-1535370213488484"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Lipton</surname><given-names>SA</given-names></name></person-group>. <article-title>Redox modulation by S-nitrosylation contributes to protein misfolding, mitochondrial dynamics, and neuronal synaptic damage in neurodegenerative diseases</article-title>. <source>Cell Death Differ</source> <year>2011</year>; <volume>18</volume>: <fpage>1478</fpage>–<lpage>86</lpage>.</citation></ref>
<ref id="bibr19-1535370213488484"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>von Bernhardi</surname><given-names>R</given-names></name><name><surname>Eugenin</surname><given-names>J</given-names></name></person-group>. <article-title>Alzheimer's disease: redox dysregulation as a common denominator for diverse pathogenic mechanisms</article-title>. <source>Antioxid Redox Signal</source> <year>2012</year>; <volume>16</volume>: <fpage>974</fpage>–<lpage>1031</lpage>.</citation></ref>
<ref id="bibr20-1535370213488484"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Yu</surname><given-names>M-H</given-names></name></person-group>. <article-title>Protein folding and disease</article-title>. <source>J Biochem Mol Biol</source> <year>2005</year>; <volume>38</volume>: <fpage>275</fpage>–<lpage>80</lpage>.</citation></ref>
<ref id="bibr21-1535370213488484"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zouambia</surname><given-names>M</given-names></name><name><surname>Fischer</surname><given-names>DF</given-names></name><name><surname>Hobo</surname><given-names>B</given-names></name><name><surname>De Vos</surname><given-names>RA</given-names></name><name><surname>Hol</surname><given-names>EM</given-names></name><name><surname>Varndell</surname><given-names>IM</given-names></name><name><surname>Sheppard</surname><given-names>PW</given-names></name><name><surname>Van Leeuwen</surname><given-names>FW</given-names></name></person-group>. <article-title>Proteasome subunit proteins and neuropathology in tauopathies and synucleinopathies: consequences for proteomic analyses</article-title>. <source>Proteomics</source> <year>2008</year>; <volume>8</volume>: <fpage>1221</fpage>–<lpage>36</lpage>.</citation></ref>
<ref id="bibr22-1535370213488484"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Butterfield</surname><given-names>DA</given-names></name><name><surname>Perluigi</surname><given-names>M</given-names></name><name><surname>Sultana</surname><given-names>R</given-names></name></person-group>. <article-title>Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics</article-title>. <source>Eur J Pharmacol</source> <year>2006</year>; <volume>545</volume>: <fpage>39</fpage>–<lpage>50</lpage>.</citation></ref>
<ref id="bibr23-1535370213488484"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schulenborg</surname><given-names>T</given-names></name><name><surname>Schmidt</surname><given-names>O</given-names></name><name><surname>van Hall</surname><given-names>A</given-names></name><name><surname>Meyer</surname><given-names>HE</given-names></name><name><surname>Hamacher</surname><given-names>M</given-names></name><name><surname>Marcus</surname><given-names>K</given-names></name></person-group>. <article-title>Proteomics in neurodegeneration – disease driven approaches</article-title>. <source>J Neural Transm</source> <year>2006</year>; <volume>113</volume>: <fpage>1055</fpage>–<lpage>73</lpage>.</citation></ref>
<ref id="bibr24-1535370213488484"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>A</given-names></name><name><surname>Portero-Otin</surname><given-names>M</given-names></name><name><surname>Pamplona</surname><given-names>R</given-names></name><name><surname>Ferrer</surname><given-names>I</given-names></name></person-group>. <article-title>Protein targets of oxidative damage in human neurodegenerative diseases with abnormal protein aggregates</article-title>. <source>Brain Pathol</source> <year>2010</year>; <volume>20</volume>: <fpage>281</fpage>–<lpage>97</lpage>.</citation></ref>
<ref id="bibr25-1535370213488484"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seehafer</surname><given-names>SS</given-names></name><name><surname>Pearce</surname><given-names>DA</given-names></name></person-group>. <article-title>You say lipofuscin, we say ceroid: defining autofluorescent storage material</article-title>. <source>Neurobiol Aging</source> <year>2006</year>; <volume>27</volume>: <fpage>576</fpage>–<lpage>88</lpage>.</citation></ref>
<ref id="bibr26-1535370213488484"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mecocci</surname><given-names>P</given-names></name><name><surname>Polidori</surname><given-names>MC</given-names></name></person-group>. <article-title>Antioxidant clinical trails in mild cognitive impairment and Alzheimer's disease</article-title>. <source>Biochim Biophys Acta</source> <year>2012</year>; <volume>1822</volume>: <fpage>631</fpage>–<lpage>8</lpage>.</citation></ref>
<ref id="bibr27-1535370213488484"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uttara</surname><given-names>B</given-names></name><name><surname>Singh</surname><given-names>AV</given-names></name><name><surname>Zamboni</surname><given-names>P</given-names></name><name><surname>Mahajan</surname><given-names>RT</given-names></name></person-group>. <article-title>Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options</article-title>. <source>Curr Neuropharmacol</source> <year>2009</year>; <volume>7</volume>: <fpage>65</fpage>–<lpage>74</lpage>.</citation></ref>
<ref id="bibr28-1535370213488484"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Palacios</surname><given-names>HH</given-names></name><name><surname>Yendluri</surname><given-names>BB</given-names></name><name><surname>Parvathaneni</surname><given-names>K</given-names></name><name><surname>Shadlinski</surname><given-names>VB</given-names></name><name><surname>Obrenovich</surname><given-names>ME</given-names></name><name><surname>Leszek</surname><given-names>J</given-names></name><name><surname>Gokhman</surname><given-names>D</given-names></name><name><surname>Gasiorowski</surname><given-names>K</given-names></name><name><surname>Bragin</surname><given-names>V</given-names></name><name><surname>Aliev</surname><given-names>G</given-names></name></person-group>. <article-title>Mitochondrion-specific anti-oxidants as drug treatments for Alzheimer disease</article-title>. <source>CNS Neurol Disord Drug Targets</source> <year>2011</year>; <volume>10</volume>: <fpage>149</fpage>–<lpage>62</lpage>.</citation></ref>
<ref id="bibr29-1535370213488484"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gomez-Pinilla</surname><given-names>F</given-names></name></person-group>. <article-title>Brain foods: the effects of nutrients on brain function</article-title>. <source>Nat Rev</source> <year>2008</year>; <volume>9</volume>: <fpage>568</fpage>–<lpage>78</lpage>.</citation></ref>
<ref id="bibr30-1535370213488484"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Riederer</surname><given-names>BM</given-names></name></person-group>. <article-title>Oxidation proteomics: the role of thiol modifications</article-title>. <source>Curr Proteomics</source> <year>2009</year>; <volume>6</volume>: <fpage>51</fpage>–<lpage>62</lpage>.</citation></ref>
<ref id="bibr31-1535370213488484"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dikshit</surname><given-names>P</given-names></name><name><surname>Goswami</surname><given-names>A</given-names></name><name><surname>Mishra</surname><given-names>A</given-names></name><name><surname>Nukina</surname><given-names>N</given-names></name><name><surname>Jana</surname><given-names>NR</given-names></name></person-group>. <article-title>Curcumin enhances the polyglutamine-expanded truncated N-terminal huntingtin-induced cell death by promoting proteasomal malfunction</article-title>. <source>Biochem Biophys Res Comm</source> <year>2006</year>; <volume>342</volume>: <fpage>1323</fpage>–<lpage>8</lpage>.</citation></ref>
<ref id="bibr32-1535370213488484"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tai</surname><given-names>H-C</given-names></name><name><surname>Schuman</surname><given-names>EM</given-names></name></person-group>. <article-title>Ubiquitin, the proteasome and protein degradation in neuronal function and dysfunction</article-title>. <source>Nat Rev Neurosci</source> <year>2008</year>; <volume>9</volume>: <fpage>826</fpage>–<lpage>38</lpage>.</citation></ref>
<ref id="bibr33-1535370213488484"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lehman</surname><given-names>NL</given-names></name></person-group>. <article-title>The ubiquitin proteasome system in neuropathology</article-title>. <source>Acta Neuropathol</source> <year>2009</year>; <volume>118</volume>: <fpage>329</fpage>–<lpage>47</lpage>.</citation></ref>
<ref id="bibr34-1535370213488484"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Olzmann</surname><given-names>JA</given-names></name><name><surname>Chin</surname><given-names>LS</given-names></name></person-group>. <article-title>Aggresome formation and neurodegenerative diseases: therapeutic implications</article-title>. <source>Curr Med Chem</source> <year>2008</year>; <volume>15</volume>: <fpage>47</fpage>–<lpage>60</lpage>.</citation></ref>
<ref id="bibr35-1535370213488484"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kosik</surname><given-names>KS</given-names></name><name><surname>Shimura</surname><given-names>H</given-names></name></person-group>. <article-title>Phosphorylated tau and the neurodegenerative foldopathies</article-title>. <source>Biochem Biophys Acta</source> <year>2005</year>; <volume>1739</volume>: <fpage>298</fpage>–<lpage>310</lpage>.</citation></ref>
<ref id="bibr36-1535370213488484"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sahara</surname><given-names>N</given-names></name><name><surname>Murayama</surname><given-names>M</given-names></name><name><surname>Mizoroki</surname><given-names>T</given-names></name><name><surname>Urushitani</surname><given-names>M</given-names></name><name><surname>Imai</surname><given-names>Y</given-names></name><name><surname>Takahashi</surname><given-names>R</given-names></name><name><surname>Murata</surname><given-names>S</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Takashima</surname><given-names>A</given-names></name></person-group>. <article-title><italic>In vivo</italic> evidence of CHIP up-regulation attenuating tau aggregation</article-title>. <source>J Neurochem</source> <year>2005</year>; <volume>94</volume>: <fpage>1254</fpage>–<lpage>63</lpage>.</citation></ref>
<ref id="bibr37-1535370213488484"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Castellani</surname><given-names>RJ</given-names></name><name><surname>Nunomura</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>H-G</given-names></name><name><surname>Perry</surname><given-names>G</given-names></name><name><surname>Smith</surname><given-names>MA</given-names></name></person-group>. <article-title>Phosphorylated tau: toxic, protective, or non of the above</article-title>. <source>J Alz Dis</source> <year>2008</year>; <volume>14</volume>: <fpage>377</fpage>–<lpage>83</lpage>.</citation></ref>
<ref id="bibr38-1535370213488484"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kabashi</surname><given-names>E</given-names></name><name><surname>Valdmanis</surname><given-names>PN</given-names></name><name><surname>Dion</surname><given-names>P</given-names></name><name><surname>Rouleau</surname><given-names>GA</given-names></name></person-group>. <article-title>Oxidized/misfolded superoxide dismutase-1: the cause of all amyotrophic lateral sclerosis?</article-title> <source>Ann Neurol</source> <year>2007</year>; <volume>62</volume>: <fpage>553</fpage>–<lpage>9</lpage>.</citation></ref>
<ref id="bibr39-1535370213488484"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Muñoz</surname><given-names>P</given-names></name><name><surname>Huenchuguala</surname><given-names>S</given-names></name><name><surname>Paris</surname><given-names>I</given-names></name><name><surname>Segura-Aguilar</surname><given-names>J</given-names></name></person-group>. <article-title>Dopamine oxidation and autophagy</article-title>. <source>Parkinsons Dis</source> <year>2012</year>; <volume>2012</volume>: <fpage>1</fpage>–<lpage>13</lpage>.</citation></ref>
<ref id="bibr40-1535370213488484"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tai</surname><given-names>H-C</given-names></name><name><surname>Serrano-Pozo</surname><given-names>A</given-names></name><name><surname>Hashimoto</surname><given-names>T</given-names></name><name><surname>Frosch</surname><given-names>MP</given-names></name><name><surname>Spires-Jones</surname><given-names>TL</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name></person-group>. <article-title>The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system</article-title>. <source>Am J Pathol</source> <year>2012</year>; <volume>181</volume>: <fpage>1426</fpage>–<lpage>35</lpage>.</citation></ref>
<ref id="bibr41-1535370213488484"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cenini</surname><given-names>G</given-names></name><name><surname>Dowling</surname><given-names>AL</given-names></name><name><surname>Beckett</surname><given-names>TL</given-names></name><name><surname>Barone</surname><given-names>E</given-names></name><name><surname>Mancuso</surname><given-names>C</given-names></name><name><surname>Murphy</surname><given-names>MP</given-names></name><name><surname>LeVine</surname><given-names>H</given-names></name><name><surname>Lott</surname><given-names>IT</given-names></name><name><surname>Schmitt</surname><given-names>FA</given-names></name><name><surname>Butterfield</surname><given-names>DA</given-names></name><name><surname>Head</surname><given-names>E</given-names></name></person-group>. <article-title>Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome</article-title>. <source>Biochim Biophys Acta</source> <year>2012</year>; <volume>1822</volume>: <fpage>130</fpage>–<lpage>8</lpage>.</citation></ref>
<ref id="bibr42-1535370213488484"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ansari</surname><given-names>MA</given-names></name><name><surname>Scheff</surname><given-names>SW</given-names></name></person-group>. <article-title>Oxidative stress in the progression of Alzheimer disease in the frontal cortex</article-title>. <source>J Neuropathol Exp Neurol</source> <year>2010</year>; <volume>69</volume>: <fpage>155</fpage>–<lpage>67</lpage>.</citation></ref>
<ref id="bibr43-1535370213488484"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Setsuie</surname><given-names>R</given-names></name><name><surname>Wada</surname><given-names>A</given-names></name></person-group>. <article-title>The functions of UCH-L1 and its relation to neurodegenerative diseases</article-title>. <source>Neurochem Int</source> <year>2007</year>; <volume>51</volume>: <fpage>105</fpage>–<lpage>11</lpage>.</citation></ref>
<ref id="bibr44-1535370213488484"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>B</given-names></name><name><surname>Cao</surname><given-names>Z</given-names></name><name><surname>Vitolo</surname><given-names>OV</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Staniszewski</surname><given-names>A</given-names></name><name><surname>Moolman</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Shelanski</surname><given-names>M</given-names></name><name><surname>Arancio</surname><given-names>O</given-names></name></person-group>. <article-title>Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory</article-title>. <source>Cell</source> <year>2006</year>; <volume>126</volume>: <fpage>775</fpage>–<lpage>88</lpage>.</citation></ref>
<ref id="bibr45-1535370213488484"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>J</given-names></name><name><surname>Levey</surname><given-names>AI</given-names></name><name><surname>Weintraub</surname><given-names>ST</given-names></name><name><surname>Rees</surname><given-names>HD</given-names></name><name><surname>Gearing</surname><given-names>M</given-names></name><name><surname>Chin</surname><given-names>LS</given-names></name><name><surname>Li</surname><given-names>L</given-names></name></person-group>. <article-title>Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinsons's disease and Alzheimer's disease</article-title>. <source>J Biol Chem</source> <year>2004</year>; <volume>279</volume>: <fpage>13256</fpage>–<lpage>64</lpage>.</citation></ref>
<ref id="bibr46-1535370213488484"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Vrij</surname><given-names>FM</given-names></name><name><surname>Fischer</surname><given-names>DF</given-names></name><name><surname>van Leeuwen</surname><given-names>FW</given-names></name><name><surname>Hol</surname><given-names>EM</given-names></name></person-group>. <article-title>Protein quality control in Alzheimer's disease by the ubiquitin proteasome system</article-title>. <source>Progr Neurobiol</source> <year>2004</year>; <volume>74</volume>: <fpage>249</fpage>–<lpage>70</lpage>.</citation></ref>
<ref id="bibr47-1535370213488484"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name></person-group>. <article-title>Quality control of the proteins associated with neurodegenerative diseases</article-title>. <source>Acta Biochim Biophys Sin</source> <year>2008</year>; <volume>40</volume>: <fpage>612</fpage>–<lpage>18</lpage>.</citation></ref>
<ref id="bibr48-1535370213488484"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yen</surname><given-names>SS</given-names></name></person-group>. <article-title>Proteasome degradation of brain cytosolic tau in Alzheimer's disease</article-title>. <source>Int J Clin Exp Pathol</source> <year>2011</year>; <volume>4</volume>: <fpage>385</fpage>–<lpage>402</lpage>.</citation></ref>
<ref id="bibr49-1535370213488484"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Keck</surname><given-names>S</given-names></name><name><surname>Nitsch</surname><given-names>R</given-names></name><name><surname>Grune</surname><given-names>T</given-names></name><name><surname>Ullrich</surname><given-names>O</given-names></name></person-group>. <article-title>Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease</article-title>. <source>J Neurochem</source> <year>2003</year>; <volume>85</volume>: <fpage>115</fpage>–<lpage>22</lpage>.</citation></ref>
<ref id="bibr50-1535370213488484"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haass</surname><given-names>C</given-names></name><name><surname>Mandelkow</surname><given-names>E</given-names></name></person-group>. <article-title>Fyn-tau-amyloid: a toxic triad</article-title>. <source>Cell</source> <year>2010</year>; <volume>142</volume>: <fpage>356</fpage>–<lpage>8</lpage>.</citation></ref>
<ref id="bibr51-1535370213488484"><label>51</label><citation citation-type="other"><comment>ElHajj Z, Riederer IM, Leuba G, Vernay A, Riederer BM. Protein ubiquitination in different regions of an Alzheimer brain. Abstract No. 68 2011, USGEB Zürich:35</comment>.</citation></ref>
<ref id="bibr52-1535370213488484"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>RP</given-names></name><name><surname>Sharad</surname><given-names>S</given-names></name><name><surname>Kapur</surname><given-names>S</given-names></name></person-group>. <article-title>Free radicals and oxidative stress in neurodegenerative diseases: relevance of dietary antioxidants</article-title>. <source>J Ind Acad Clin Med</source> <year>2004</year>; <volume>5</volume>: <fpage>218</fpage>–<lpage>25</lpage>.</citation></ref>
<ref id="bibr53-1535370213488484"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cowan</surname><given-names>CM</given-names></name><name><surname>Raymond</surname><given-names>LA</given-names></name></person-group>. <article-title>Selective neuronal degeneration in Huntington's disease</article-title>. <source>Curr Top Dev Biol</source> <year>2006</year>; <volume>75</volume>: <fpage>25</fpage>–<lpage>71</lpage>.</citation></ref>
<ref id="bibr54-1535370213488484"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Delobel</surname><given-names>P</given-names></name><name><surname>Leroy</surname><given-names>O</given-names></name><name><surname>Hamdane</surname><given-names>M</given-names></name><name><surname>Sambo</surname><given-names>AV</given-names></name><name><surname>Delacourte</surname><given-names>A</given-names></name><name><surname>Buée</surname><given-names>L</given-names></name></person-group>. <article-title>Proteasome inhibition and tau proteolysis: an unexpected regulation</article-title>. <source>FEBS Lett</source> <year>2005</year>; <volume>579</volume>: <fpage>1</fpage>–<lpage>5</lpage>.</citation></ref>
<ref id="bibr55-1535370213488484"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Navarrete</surname><given-names>LP</given-names></name><name><surname>Pérez</surname><given-names>P</given-names></name><name><surname>Morales</surname><given-names>I</given-names></name><name><surname>Maccioni</surname><given-names>RB</given-names></name></person-group>. <article-title>Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies</article-title>. <source>Curr Alz Res</source> <year>2011</year>; <volume>8</volume>: <fpage>678</fpage>–<lpage>85</lpage>.</citation></ref>
<ref id="bibr56-1535370213488484"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cristalli</surname><given-names>DO</given-names></name><name><surname>Arnal</surname><given-names>N</given-names></name><name><surname>Marra</surname><given-names>FA</given-names></name><name><surname>Alaniz</surname><given-names>MJT</given-names></name><name><surname>Marra</surname><given-names>CA</given-names></name></person-group>. <article-title>Peripheral markers in neurodegegenrative patients and their first-degree relatives</article-title>. <source>J Neurol Sci</source> <year>2012</year>; <volume>314</volume>: <fpage>48</fpage>–<lpage>56</lpage>.</citation></ref>
<ref id="bibr57-1535370213488484"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Di Domenico</surname><given-names>F</given-names></name><name><surname>Coccia</surname><given-names>R</given-names></name><name><surname>Butterfield</surname><given-names>DA</given-names></name><name><surname>Perluigi</surname><given-names>M</given-names></name></person-group>. <article-title>Circulating biomarkers of protein oxidation for Alzheimer disease: expectations within limits</article-title>. <source>Biochim Biophys Acta</source> <year>2011</year>; <volume>1814</volume>: <fpage>1785</fpage>–<lpage>95</lpage>.</citation></ref>
<ref id="bibr58-1535370213488484"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>James</surname><given-names>SA</given-names></name><name><surname>Volitakis</surname><given-names>I</given-names></name><name><surname>Adlard</surname><given-names>PA</given-names></name><etal/></person-group>. <article-title>Elevated labile Cu is associated with oxidative pathology in Alzheimer disease</article-title>. <source>Free Rad Biol Med</source> <year>2012</year>; <volume>52</volume>: <fpage>298</fpage>–<lpage>302</lpage>.</citation></ref>
<ref id="bibr59-1535370213488484"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Rettberg</surname><given-names>JR</given-names></name><name><surname>Klosinski</surname><given-names>LP</given-names></name><name><surname>Cadenas</surname><given-names>E</given-names></name><name><surname>Brinton</surname><given-names>RD</given-names></name></person-group>. <article-title>Shift in brain metabolism in late onset Alzheimers's disease: implications for biomarkers and therapeutic interventions</article-title>. <source>Mol Aspects Med</source> <year>2011</year>; <volume>32</volume>: <fpage>247</fpage>–<lpage>57</lpage>.</citation></ref>
<ref id="bibr60-1535370213488484"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>HE</given-names></name><name><surname>Kwon</surname><given-names>I</given-names></name></person-group>. <article-title>Xanthene food dye, as a modulator of Alzheimer's disease amyloid-beta peptide aggregartion and the associated impaired neuronal cell function</article-title>. <source>Plos ONE</source> <year>2011</year>; <volume>6</volume>: <fpage>e25752</fpage>–<lpage>e25752</lpage>.</citation></ref>
<ref id="bibr61-1535370213488484"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pocernich</surname><given-names>CB</given-names></name><name><surname>Butterfield</surname><given-names>DA</given-names></name></person-group>. <article-title>Elevation of glutathione as a therapeutic strategy in Alzheimer's disease</article-title>. <source>Biochim Biophys Acta</source> <year>2012</year>; <volume>1822</volume>: <fpage>625</fpage>–<lpage>30</lpage>.</citation></ref>
<ref id="bibr62-1535370213488484"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Farr</surname><given-names>SA</given-names></name><name><surname>Poon</surname><given-names>HF</given-names></name><name><surname>Dogrukol-Ak</surname><given-names>D</given-names></name><name><surname>Drake</surname><given-names>J</given-names></name><name><surname>Banks</surname><given-names>WA</given-names></name><name><surname>Eyerman</surname><given-names>E</given-names></name><name><surname>Butterfield</surname><given-names>DA</given-names></name><name><surname>Morley</surname><given-names>JE</given-names></name></person-group>. <article-title>The antioxidant -lipoic acid and <italic>N</italic>-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice</article-title>. <source>J Neurochem</source> <year>2003</year>; <volume>84</volume>: <fpage>1173</fpage>–<lpage>83</lpage>.</citation></ref>
<ref id="bibr63-1535370213488484"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>das Neves Duarte</surname><given-names>JM</given-names></name><name><surname>Kulak</surname><given-names>A</given-names></name><name><surname>Gholam-Razaee</surname><given-names>MM</given-names></name><name><surname>Cuenod</surname><given-names>M</given-names></name><name><surname>Gruetter</surname><given-names>R</given-names></name><name><surname>Do</surname><given-names>KQ</given-names></name></person-group>. <article-title><italic>N</italic>-acetylcysteine normalizes neurochemical changes in the glutathione-deficient schizophrenia mouse model during development</article-title>. <source>Biol Psy</source> <year>2012</year>; <volume>71</volume>: <fpage>1006</fpage>–<lpage>14</lpage>.</citation></ref>
<ref id="bibr64-1535370213488484"><label>64</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Riederer</surname><given-names>IM</given-names></name><name><surname>Moreno Herrero</surname><given-names>R</given-names></name><name><surname>Leuba</surname><given-names>G</given-names></name><name><surname>Riederer</surname><given-names>BM</given-names></name></person-group>. <article-title>Serial protein labeling with infrared maleimide dyes to identify cysteine modifications</article-title>. <source>J Proteomics</source> <year>2008</year>; <volume>71</volume>: <fpage>222</fpage>–<lpage>30</lpage>.</citation></ref>
</ref-list>
</back>
</article>